One2Treat Raises Capital with Seed Extension

One2Treat SA, a technology company transforming how the patient voice is integrated into clinical development, has completed a planned seed extension to accelerate its software platform development.

The conclusion of One2Treat’s planned seed extension funding round marks a milestone in the company’s growth. This investment follows the successful deployment of the One2Treat Insights module across multiple live projects and the recent release of the One2Treat Voice module. It reflects the confidence of initial shareholders in One2Treat’s approach to answer the growing needs of the biopharma industry to both increase productivity and better reflect what matters to patients and clinicians.

The funding supports the continued development and scaling of One2Treat’s cloud-based software platform, which integrates diverse patient-focused outcomes into a single, comprehensive assessment of treatment effects, enabling a clearer understanding of the Net Treatment Benefit. The platform answers strategic needs for clinical development decisions but also supports the overall medical value of a new treatment during regulatory discussions, HTA and commercialization.

Alongside the capital increase, One2Treat has moved to a new office in Louvain-la-Neuve, an academic and tech ecosystem just outside Brussels.

“The new space provides a larger, more modern and collaborative environment for the expanding team, fostering innovation and facilitating closer partnerships with key academic and industry stakeholders,” said Marc Buyse, Founder One2Treat.